Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV

Mohiuddin Hadi, Stephen L. Bacharach, Millie Whatley, Steven K. Libutti, Stephen E. Straus, V. Koneti Rao, Robert Wesley, Jorge A. Carrasquillo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: 2-Deoxy-2[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) has an established role in the evaluation of cancer. Generally, tumor uptake and response to treatment are evaluated using the standardized uptake value (SUV). Some authors have proposed correcting SUV for glucose levels. Insulin is also thought to influence tumor uptake by changing uptake in other tissues. However, little attention has been paid to understanding the variability of glucose or insulin during a single PET study. Method: We studied the biological and instrumental variability of glucose and insulin measurements in 71 nondiabetic patients undergoing FDG-PET studies. Multiple glucose measurements were obtained in all 71 subjects, and in 69 of these 71 subjects, multiple serum insulin measurements were made. We determined the coefficient of observed variation (CVow) and the coefficient of variation attributable to biological variability (CVbv) for both glucose and insulin. Results: The mean glucose concentration was 78.9±13.5 mg/dl. The mean insulin value was 6.49±5.92 μU/ml. The weighted mean CVow and CVbv was 5.0% and 3.6%, respectively, for glucose and 14.2% and 8.3%, respectively, for insulin. Conclusions: Variations in the range of 3.6% are observed in glucose measurements during the time course of an FDG scan even after accounting for analytical error; larger variations of 8.3% are observed in insulin levels. Therefore, corrections of SUV for blood glucose, especially if obtained from single measurements, can introduce additional errors of at least this much.

Original languageEnglish (US)
Pages (from-to)441-445
Number of pages5
JournalNuclear Medicine and Biology
Volume35
Issue number4
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Insulin
Glucose
Neoplasms
Blood Glucose

Keywords

  • FDG-PET
  • Glucose
  • Insulin
  • PET
  • PET/CT
  • Variability

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV. / Hadi, Mohiuddin; Bacharach, Stephen L.; Whatley, Millie; Libutti, Steven K.; Straus, Stephen E.; Rao, V. Koneti; Wesley, Robert; Carrasquillo, Jorge A.

In: Nuclear Medicine and Biology, Vol. 35, No. 4, 05.2008, p. 441-445.

Research output: Contribution to journalArticle

Hadi, M, Bacharach, SL, Whatley, M, Libutti, SK, Straus, SE, Rao, VK, Wesley, R & Carrasquillo, JA 2008, 'Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV', Nuclear Medicine and Biology, vol. 35, no. 4, pp. 441-445. https://doi.org/10.1016/j.nucmedbio.2008.02.007
Hadi, Mohiuddin ; Bacharach, Stephen L. ; Whatley, Millie ; Libutti, Steven K. ; Straus, Stephen E. ; Rao, V. Koneti ; Wesley, Robert ; Carrasquillo, Jorge A. / Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV. In: Nuclear Medicine and Biology. 2008 ; Vol. 35, No. 4. pp. 441-445.
@article{5f0b4a8263a04bc3a214a7eac6ba65bf,
title = "Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the {"}glucose-corrected{"} SUV",
abstract = "Introduction: 2-Deoxy-2[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) has an established role in the evaluation of cancer. Generally, tumor uptake and response to treatment are evaluated using the standardized uptake value (SUV). Some authors have proposed correcting SUV for glucose levels. Insulin is also thought to influence tumor uptake by changing uptake in other tissues. However, little attention has been paid to understanding the variability of glucose or insulin during a single PET study. Method: We studied the biological and instrumental variability of glucose and insulin measurements in 71 nondiabetic patients undergoing FDG-PET studies. Multiple glucose measurements were obtained in all 71 subjects, and in 69 of these 71 subjects, multiple serum insulin measurements were made. We determined the coefficient of observed variation (CVow) and the coefficient of variation attributable to biological variability (CVbv) for both glucose and insulin. Results: The mean glucose concentration was 78.9±13.5 mg/dl. The mean insulin value was 6.49±5.92 μU/ml. The weighted mean CVow and CVbv was 5.0{\%} and 3.6{\%}, respectively, for glucose and 14.2{\%} and 8.3{\%}, respectively, for insulin. Conclusions: Variations in the range of 3.6{\%} are observed in glucose measurements during the time course of an FDG scan even after accounting for analytical error; larger variations of 8.3{\%} are observed in insulin levels. Therefore, corrections of SUV for blood glucose, especially if obtained from single measurements, can introduce additional errors of at least this much.",
keywords = "FDG-PET, Glucose, Insulin, PET, PET/CT, Variability",
author = "Mohiuddin Hadi and Bacharach, {Stephen L.} and Millie Whatley and Libutti, {Steven K.} and Straus, {Stephen E.} and Rao, {V. Koneti} and Robert Wesley and Carrasquillo, {Jorge A.}",
year = "2008",
month = "5",
doi = "10.1016/j.nucmedbio.2008.02.007",
language = "English (US)",
volume = "35",
pages = "441--445",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV

AU - Hadi, Mohiuddin

AU - Bacharach, Stephen L.

AU - Whatley, Millie

AU - Libutti, Steven K.

AU - Straus, Stephen E.

AU - Rao, V. Koneti

AU - Wesley, Robert

AU - Carrasquillo, Jorge A.

PY - 2008/5

Y1 - 2008/5

N2 - Introduction: 2-Deoxy-2[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) has an established role in the evaluation of cancer. Generally, tumor uptake and response to treatment are evaluated using the standardized uptake value (SUV). Some authors have proposed correcting SUV for glucose levels. Insulin is also thought to influence tumor uptake by changing uptake in other tissues. However, little attention has been paid to understanding the variability of glucose or insulin during a single PET study. Method: We studied the biological and instrumental variability of glucose and insulin measurements in 71 nondiabetic patients undergoing FDG-PET studies. Multiple glucose measurements were obtained in all 71 subjects, and in 69 of these 71 subjects, multiple serum insulin measurements were made. We determined the coefficient of observed variation (CVow) and the coefficient of variation attributable to biological variability (CVbv) for both glucose and insulin. Results: The mean glucose concentration was 78.9±13.5 mg/dl. The mean insulin value was 6.49±5.92 μU/ml. The weighted mean CVow and CVbv was 5.0% and 3.6%, respectively, for glucose and 14.2% and 8.3%, respectively, for insulin. Conclusions: Variations in the range of 3.6% are observed in glucose measurements during the time course of an FDG scan even after accounting for analytical error; larger variations of 8.3% are observed in insulin levels. Therefore, corrections of SUV for blood glucose, especially if obtained from single measurements, can introduce additional errors of at least this much.

AB - Introduction: 2-Deoxy-2[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) has an established role in the evaluation of cancer. Generally, tumor uptake and response to treatment are evaluated using the standardized uptake value (SUV). Some authors have proposed correcting SUV for glucose levels. Insulin is also thought to influence tumor uptake by changing uptake in other tissues. However, little attention has been paid to understanding the variability of glucose or insulin during a single PET study. Method: We studied the biological and instrumental variability of glucose and insulin measurements in 71 nondiabetic patients undergoing FDG-PET studies. Multiple glucose measurements were obtained in all 71 subjects, and in 69 of these 71 subjects, multiple serum insulin measurements were made. We determined the coefficient of observed variation (CVow) and the coefficient of variation attributable to biological variability (CVbv) for both glucose and insulin. Results: The mean glucose concentration was 78.9±13.5 mg/dl. The mean insulin value was 6.49±5.92 μU/ml. The weighted mean CVow and CVbv was 5.0% and 3.6%, respectively, for glucose and 14.2% and 8.3%, respectively, for insulin. Conclusions: Variations in the range of 3.6% are observed in glucose measurements during the time course of an FDG scan even after accounting for analytical error; larger variations of 8.3% are observed in insulin levels. Therefore, corrections of SUV for blood glucose, especially if obtained from single measurements, can introduce additional errors of at least this much.

KW - FDG-PET

KW - Glucose

KW - Insulin

KW - PET

KW - PET/CT

KW - Variability

UR - http://www.scopus.com/inward/record.url?scp=43049171680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049171680&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2008.02.007

DO - 10.1016/j.nucmedbio.2008.02.007

M3 - Article

C2 - 18482681

AN - SCOPUS:43049171680

VL - 35

SP - 441

EP - 445

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 4

ER -